Effect of plasmodium yoelii exposure on vaccination with the 19-kilodalton carboxyl terminus of merozoite surface protein 1 and vice versa and implications for the application of a human malaria vaccine

Infection and Immunity

Volumn 77, Issue 2, 2009, Pages 817-824

  Wipasa, Jiraprapa ^a,b   Xu, Huji ^a,c   Liu, Xueqin ^a   Hirunpeteharat, Chakrit ^d   Towers, Anthony S ^e   Good, Michael F ^a  

^a ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^b CHIANG MAI UNIVERSITY   (Thailand)

^c SECOND MILITARY MEDICAL UNIVERSITY   (China)

^d MAHIDOL UNIVERSITY   (Thailand)

^e NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN G2B; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN M; MALARIA VACCINE; MEROZOITE SURFACE PROTEIN 1; PARASITE ANTIBODY; RECOMBINANT PROTEIN; PROTOZOON ANTIBODY; SUBUNIT VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; EXPOSURE; FEMALE; IMMUNE RESPONSE; IMMUNOMODULATION; MALARIA; MOUSE; NONHUMAN; PARASITEMIA; PLASMODIUM YOELII; PRIORITY JOURNAL; TREATMENT RESPONSE; VACCINATION; ANIMAL; BAGG ALBINO MOUSE; BLOOD; HUMAN; IMMUNOLOGY;

ANIMALS; ANTIBODIES, PROTOZOAN; FEMALE; HUMANS; MALARIA; MALARIA VACCINES; MEROZOITE SURFACE PROTEIN 1; MICE; MICE, INBRED BALB C; PLASMODIUM YOELII; VACCINES, SUBUNIT;

EID: 60549093566     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.01063-08     Document Type: Article

References (19)

1. Daly, T. M., and C. A. Long. 1995. Humoral response to a carboxyl-terminal region of the merozoite surface protein-1 plays a predominant role in controlling blood-stage infection in rodent malaria. J. Immunol. 155:236-243.
2. Egan, A. F., M. J. Blackman, and D. C. Kaslow. 2000. Vaccine efficacy of recombinant Plasmodium falciparum merozoite surface protein 1 in malaria-naive, -exposed, and/or -rechallenged Aotus vociferous monkeys. Infect. Immun. 68:1418-1427.
3. Fazekas de St Groth, S. 1967. Cross recognition and cross reactivity. Cold Spring Harbor Symp. Quant. Biol. 32:525.
4. Francis, T., Jr. 1953. Influenza: the new acquayantance. Ann. Intern. Med. 39:203-221.
5. Franks, S., L. Baton, K. Tetteh, E. Tongren, D. Dewin, B. D. Akanmori, K. A. Koram, L. Ranford-Cartwright, and E. M. Riley. 2003. Genetic diversity and antigenic polymorphism in Plasmodium falcipamm: extensive serological cross-reactivity between allelic variants of merozoite surface protein 2. Infect. Immun. 71:3485-3495.
6. Good, M. F., D. C. Kaslow, and L. H. Miller. 1998. Pathways and strategies for developing a malaria blood-stage vaccine. Annu. Rev. Immunol. 16:57-87.
7. 19) induces protective immunity to blood stage malaria infection in mice. Parasite Immunol. 20:413-420.
8. + T cells. J. Immunol. 159:3400-3411.
9. Hirunpetcharat, C., P. VukoviC., X. Q. Liu, D. C. Kaslow, L. H. Miller, and M. F. Good. 1999. Absolute requirement for an active immune response involving B cells and Th cells in immunity to Plasmodium yoelii passively acquired with antibodies to the 19-kDa carboxyl-terminal fragment of merozoite surface protein-1. J. Immunol. 162:7309-7314.
10. Ho, M., H. K. Webster, S. Looareesuwan, W. Supanaranond, R. E. Phillips, P. Chanthavanich, and D. A. Warrell. 1986. Antigen-specific immunosuppression in human malaria due to Plasmodium falciparum. J. Infect. Dis. 153:763-771.
11. Kumar, S., W. Collins, A. Egan, A. Yadava, O. Garraud, M. J. Blackman, J. A. Guevara Patino, C. Diggs, and D. C. Kaslow. 2000. Immunogenicity and efficacy in aotus monkeys of four recombinant Plasmodium falciparum vaccines in multiple adjuvant formulations based on the 19-kilodalton C terminus of merozoite surface protein 1. Infect. Immun. 68:2215-2223.
12. Kumar, S., A. Yadava, D. B. Keister, J. H. Tian, M. Ohl, K. A. Perdue-Greenfield, L. H. Miller, and D. C. Kaslow. 1995. Immunogenicity and in vivo efficacy of recombinant Plasmodium falciparum merozoite surface protein-1 in Aotus monkeys. Mol. Med. 1:325-332.
13. Perraut, R., O. Mercereau-Puijalon, D. Mattei, E. Bourreau, O. Garraud, B. Bonnemains, L. Pereia de Silva, and J. C. Michel. 1995. Induction of opsonizing antibodies after injection of recombinant Plasmodium falciparum vaccine candidate antigens in preimmune Saimiri sciureus monkeys. Infect. Immun. 63:554-562.
14. StanisiC., D. I., L. B. Martin, X. Q. Liu, D. Jackson, J. Cooper, and M. F. Good. 2003. Analysis of immunological nonresponsiveness to the 19-kilodalton fragment of merozoite surface protein 1 of Plasmodium yoelii: rescue by chemical conjugation to diphtheria toxoid (DT) and enhancement of immunogenicity by prior DT vaccination. Infect. Immun. 71:5700-5713.
15. Taylor, R. R., A. Egan, D. McGuinness, A. Jepson, R. Adair, C. Drakely, and E. Riley. 1996. Selective recognition of malaria antigens by human serum antibodies is not genetically determined but demonstrates some features of clonal imprinting. Int. Immunol. 8:905-915.
16. Tian, J. H., L. H. Miller, D. C. Kaslow, J. Ahlers, M. F. Good, D. W. Ailing, J. A. Berzofsky, and S. Kumar. 1996. Genetic regulation of protective immune response in congenic strains of mice vaccinated with a subunit malaria vaccine. J. Immunol. 157:1176-1183.
17. Weisman, S., L. Wang, H. Billman-Jacobe, D. H. Nhan, T. L. Richie, and R, L. Coppel. 2001. Antibody responses to infections with strains of Plasmodium falciparum expressing diverse forms of merozoite surface protein 2. Infect. Immun. 69:959-967.
18. Wipasa, J., H. Xu, A. Stowers, and M. F, Good. 2001. Apoptotic deletion of Th cells specific for the 19-kDa carboxyl-terminal fragment of merozoite surface protein 1 during malaria infection. J. Immunol. 167:3903-3909.
19. Wykes, M. N., Y. H. Zhou, X. Q. Liu, and M. F. Good. 2005. Plasmodium yoelii can ablate vaccine-induced long-term protection in mice. J. Immunol. 175:2510-2516.